Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202308016446i

Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202306214781i

Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202304289604i

Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202304200337i

Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202304184914i

Article Source : 머니투데이
Link : https://news.mt.co.kr/mtview.php?no=2023040314334967730

Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202303162439i

Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202303159193i

Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202302033591i

Article Source : PR Newswire
Link : https://www.prnewswire.com/news-releases/qurient-co-ltd-and-tb-alliance-announce-exclusive-license-agreement-for-telacebec-q203-a-new-anti-tuberculosis-agent-301738149.html

Article Source : 바이오스펙테이터
Link : http://www.biospectator.com/view/news_view.php?varAtcId=18181

Article Source : Business Wire
Link : https://www.businesswire.com/news/home/20230202005011/en/Qurient-Announces-Dosing-of-First-Patient-in-Q702-in-Combination-with-KEYTRUDA%C2%AE-in-a-Phase-1b2-Clinical-Study-for-the-Treatment-of-Patients-with-Solid-Tumors

Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202301193813i

Article Source : 머니투데이
Link : https://news.mt.co.kr/mtview.php?no=2022120109525454587